Multiparametric bone MRI can improve CT-guided bone biopsy target selection in cancer patients and increase diagnostic yield and feasibility of next-generation tumour sequencing.
Bone marrow
Genomics
Image-guided biopsy
Magnetic resonance imaging
Neoplasms
Journal
European radiology
ISSN: 1432-1084
Titre abrégé: Eur Radiol
Pays: Germany
ID NLM: 9114774
Informations de publication
Date de publication:
Jul 2022
Jul 2022
Historique:
received:
17
08
2021
accepted:
20
12
2021
revised:
17
12
2021
pubmed:
30
1
2022
medline:
24
6
2022
entrez:
29
1
2022
Statut:
ppublish
Résumé
To evaluate whether multiparametric bone MRI (mpBMRI) utilising a combination of DWI signal, ADC and relative fat-fraction (rFF) can identify bone metastases, which provide high diagnostic biopsy yield and next-generation genomic sequencing (NGS) feasibility. A total of 150 CT-guided bone biopsies performed by interventional radiologists (3/2013 to 2/2021) at our centre were reviewed. In 43 patients, contemporaneous DWI and rFF images, calculated from 2-point T1w Dixon MRI, were available. For each biopsied lesion, a region of interest (ROI) was delineated on ADC and rFF images and the following MRI parameters were recorded: visual classification of DWI signal intensity (SI), mean, median, 10th and 90th centile ADC and rFF values. Non-parametric tests were used to compare values between tumour positive/negative biopsies and feasible/non-feasible NGS, with p-values < 0.05 deemed significant. The mpBMRI combination high DWI signal, mean ADC < 1100 µm MpBMRI utilising the combination of DWI signal, ADC and rFF can identify active bone metastases, which provide biopsy tissue with high diagnostic yield and NGS feasibility. • Multiparametric bone MRI with diffusion-weighted and relative fat-fraction images helps to identify active bone metastases suitable for CT-guided biopsy. • Target lesions for CT-guided bone biopsies in cancer patients can be chosen with greater confidence. • CT-guided bone biopsy success rates, especially yielding sufficient viable tissue for advanced molecular tissue analyses, can be improved.
Identifiants
pubmed: 35092476
doi: 10.1007/s00330-022-08536-6
pii: 10.1007/s00330-022-08536-6
pmc: PMC9213271
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4647-4656Subventions
Organisme : Movember Foundation
ID : CE013_2-002
Informations de copyright
© 2022. The Author(s).
Références
Sailer V, Schiffman MH, Kossai M et al (2018) Bone biopsy protocol for advanced prostate cancer in the era of precision medicine. Cancer 124(5):1008–1015
doi: 10.1002/cncr.31173
Bradley E (2012) Incorporating biomarkers into clinical trial designs: points to consider. Nat Biotechnol 30(7):596–599
doi: 10.1038/nbt.2296
Suh CH, Yun SJ (2019) Diagnostic outcome of image-guided percutaneous core needle biopsy of sclerotic bone lesions: a meta-analysis AJR Am J Roentgenol 212(3):625–631
pubmed: 30589380
Li Y, Du Y, Luo TY et al (2014) Factors influencing diagnostic yield of CT-guided percutaneous core needle biopsy for bone lesions. Clin Radiol 69(1):e43–e47
doi: 10.1016/j.crad.2013.09.003
Wu JS, Goldsmith JD, Horwich PJ, Shetty SK, Hochman MG (2008) Bone and soft-tissue lesions: what factors affect diagnostic yield of image-guided core-needle biopsy? Radiology 248(3):962–970
doi: 10.1148/radiol.2483071742
Holmes MG, Foss E, Joseph G et al (2017) CT-guided bone biopsies in metastatic castration-resistant prostate cancer: factors predictive of maximum tumor yield. J Vasc Interv Radiol 28(8):1073–81.e1
doi: 10.1016/j.jvir.2017.04.019
Hao DJ, Sun HH, He BR, Liu TJ, Jiang YH, Zhao QP (2011) Accuracy of CT-guided biopsies in 158 patients with thoracic spinal lesions. Acta Radiol 52(9):1015–1019
doi: 10.1258/AR.2011.110172
Hwang S, Lefkowitz RA, Landa J et al (2011) Percutaneous CT-guided bone biopsy: diagnosis of malignancy in lesions with initially indeterminate biopsy results and CT features associated with diagnostic or indeterminate results. AJR Am J Roentgenol 197(6):1417–1425
doi: 10.2214/AJR.11.6820
Omura MC, Motamedi K, UyBico S, Nelson SD, Seeger LL (2011) Revisiting CT-guided percutaneous core needle biopsy of musculoskeletal lesions: contributors to biopsy success. AJR Am J Roentgenol 197(2):457–461
doi: 10.2214/AJR.10.6145
Spritzer CE, Afonso PD, Vinson EN et al (2013) Bone marrow biopsy: RNA isolation with expression profiling in men with metastatic castration-resistant prostate cancer–factors affecting diagnostic success. Radiology 269(3):816–823
doi: 10.1148/radiol.13121782
McKay RR, Zukotynski KA, Werner L et al (2014) Imaging, procedural and clinical variables associated with tumor yield on bone biopsy in metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 17(4):325–331
doi: 10.1038/pcan.2014.28
Smits M, Ekici K, Pamidimarri Naga S, et al. (2020) Prior PSMA PET-CT imaging and Hounsfield unit impact on tumor yield and success of molecular analyses from bone biopsies in metastatic prostate cancer. Cancers (Basel) 12(12).
Smits M, Mehra N, Sedelaar M, Gerritsen W, Schalken JA (2017) Molecular biomarkers to guide precision medicine in localized prostate cancer. Expert Rev Mol Diagn 17(8):791–804
doi: 10.1080/14737159.2017.1345627
Ní Mhuircheartaigh J, McMahon C, Lin YC, Wu J (2017) Diagnostic yield of percutaneous biopsy for sclerotic bone lesions: influence of mean Hounsfield units. Clin Imaging 46:53–56
doi: 10.1016/j.clinimag.2017.06.008
Wu MH, Xiao LF, Liu HW et al (2019) PET/CT-guided versus CT-guided percutaneous core biopsies in the diagnosis of bone tumors and tumor-like lesions: which is the better choice? Cancer Imaging 19(1):69
doi: 10.1186/s40644-019-0253-1
Guo W, Hao B, Chen HJ et al (2017) PET/CT-guided percutaneous biopsy of FDG-avid metastatic bone lesions in patients with advanced lung cancer: a safe and effective technique. Eur J Nucl Med Mol Imaging 44(1):25–32
doi: 10.1007/s00259-016-3455-9
de Jong AC, Smits M, van Riet J et al (2020) Ga-PSMA-guided bone biopsies for molecular diagnostics in patients with metastatic prostate cancer. J Nucl Med 61(11):1607–1614
doi: 10.2967/jnumed.119.241109
van Steenbergen TRF, Smits M, Scheenen TWJ et al (2020) Ga-PSMA-PET/CT and diffusion MRI targeting for cone-beam CT-guided bone biopsies of castration-resistant prostate cancer patients. Cardiovasc Intervent Radiol 43(1):147–154
doi: 10.1007/s00270-019-02312-8
Messiou C, Hillengass J, Delorme S et al (2019) Guidelines for acquisition, interpretation, and reporting of whole-body MRI in myeloma: Myeloma Response Assessment and Diagnosis System (MY-RADS). Radiology 291(1):5–13
doi: 10.1148/radiol.2019181949
Padhani AR, Lecouvet FE, Tunariu N et al (2017) METastasis Reporting and Data System for Prostate Cancer: practical guidelines for acquisition, interpretation, and reporting of whole-body magnetic resonance imaging-based evaluations of multiorgan involvement in advanced prostate cancer. Eur Urol 71(1):81–92
doi: 10.1016/j.eururo.2016.05.033
Nonomura Y, Yasumoto M, Yoshimura R et al (2001) Relationship between bone marrow cellularity and apparent diffusion coefficient. J Magn Reson Imaging 13(5):757–760
doi: 10.1002/jmri.1105
Perez-Lopez R, Nava Rodrigues D, Figueiredo I et al (2018) Multiparametric magnetic resonance imaging of prostate cancer bone disease: correlation with bone biopsy histological and molecular features. Invest Radiol 53(2):96–102
doi: 10.1097/RLI.0000000000000415
Dixon WT (1984) Simple proton spectroscopic imaging. Radiology 153(1):189–194
doi: 10.1148/radiology.153.1.6089263
Rosen BR, Fleming DM, Kushner DC et al (1988) Hematologic bone marrow disorders: quantitative chemical shift MR imaging. Radiology 169(3):799–804
doi: 10.1148/radiology.169.3.3187003
Donners R, Blackledge M, Tunariu N, Messiou C, Merkle EM, Koh DM (2018) Quantitative whole-body diffusion-weighted MR imaging. Magn Reson Imaging Clin N Am 26(4):479–494
doi: 10.1016/j.mric.2018.06.002
Giles SL, Messiou C, Collins DJ et al (2014) Whole-body diffusion-weighted MR imaging for assessment of treatment response in myeloma. Radiology 271(3):785–794
doi: 10.1148/radiol.13131529
Messiou C, Collins DJ, Morgan VA, Desouza NM (2011) Optimising diffusion weighted MRI for imaging metastatic and myeloma bone disease and assessing reproducibility. Eur Radiol 21(8):1713–1718
doi: 10.1007/s00330-011-2116-4
Barwick T, Orton M, Koh DM et al (2021) Repeatability and reproducibility of apparent diffusion coefficient and fat fraction measurement of focal myeloma lesions on whole body magnetic resonance imaging. Br J Radiol 94(1120):20200682
doi: 10.1259/bjr.20200682
Koh DM, Blackledge M, Collins DJ et al (2009) Reproducibility and changes in the apparent diffusion coefficients of solid tumours treated with combretastatin A4 phosphate and bevacizumab in a two-centre phase I clinical trial. Eur Radiol 19(11):2728–2738
doi: 10.1007/s00330-009-1469-4
Noble JJ, Keevil SF, Totman J, Charles-Edwards GD (2014) In vitro and in vivo comparison of two-, three- and four-point Dixon techniques for clinical intramuscular fat quantification at 3 T. Br J Radiol 87(1036):20130761
doi: 10.1259/bjr.20130761
Donners R, Obmann MM, Boll D, Gutzeit A, Harder D (2020) Dixon or DWI - comparing the utility of fat fraction and apparent diffusion coefficient to distinguish between malignant and acute osteoporotic vertebral fractures. Eur J Radiol. 132:109342.
Iima M, Partridge SC, Le Bihan D (2020) Six DWI questions you always wanted to know but were afraid to ask: clinical relevance for breast diffusion MRI. Eur Radiol 30(5):2561–2570
doi: 10.1007/s00330-019-06648-0